-- Presentation to be webcast on www.exelixis.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 19, 2017--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s President and Chief Executive Officer, will provide
an overview of the company at the Cantor Fitzgerald Healthcare
Conference taking place September 25-27 in New York, NY. The Exelixis
presentation is scheduled for 3:00 PM EDT / 12:00 PM PDT on Monday,
September 25, 2017.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the presentation to ensure adequate time for
any software download that may be required to listen to the webcast. A
replay will also be available at the same location for 14 days.
Founded in 1994, Exelixis,
Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused
biotechnology company that strives to accelerate the discovery,
development and commercialization of new medicines for
difficult-to-treat cancers. Following early work in model genetic
systems, we established a broad drug discovery and development platform
that has served as the foundation for our continued efforts to bring new
cancer therapies to patients in need. We discovered our lead compounds,
cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring them to patients
globally. With growing revenues from the three resulting commercialized
products – CABOMETYX®, COMETRIQ®, and COTELLIC®
– we are reinvesting in our business to maximize the potential of our
pipeline, which we intend to supplement with targeted business
development activities and internal drug discovery, all to deliver the
next generation of Exelixis medicines and help patients recover stronger
and live longer. For more information about Exelixis, please visit www.exelixis.com
or follow @ExelixisInc on Twitter.
Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are
registered U.S. trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170919006540/en/
Source: Exelixis, Inc.
EVP, Public Affairs and Investor
Hal Mackins, 415-994-0040